Record Net Sales of 1.473 Billion USD in Q1 Driven by Strategic Initiatives and Innovative Products
Galderma Group AG, a prominent player in the dermatology field, has reported remarkable growth in its first-quarter results for 2026. The company’s net sales reached an impressive 1.473 billion USD, representing a year-on-year increase of 25.5% at constant currency. This robust performance underscores the effectiveness of Galderma’s integrated dermatology strategy, which hinges on innovation and a commitment to addressing the evolving needs of consumers across various geographical markets.
The surge in sales was largely attributed to volume growth, which was enhanced by favorable pricing and product mix effects. Notably, Galderma’s diverse product portfolio, spanning Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology, contributed significantly to its overall revenue for the quarter. The company’s performance was particularly strong in regions where it introduced new products and expanded its market presence, providing an optimistic outlook for the remainder of the year.
In terms of product categories, both Injectable Aesthetics and Dermatological Skincare experienced substantial growth. Injectable Aesthetics saw net sales of 648 million USD, marking a 13.1% increase, while Therapeutic Dermatology achieved a remarkable 71.3% growth, with net sales reaching 385 million USD. This position reflects Galderma’s strategic focus on delivering innovative and effective therapeutic solutions, particularly amid growing demand for dermatological care solutions.
Continued Innovation Driving Growth in Injectable Aesthetics
Galderma’s Injectable Aesthetics division remains a cornerstone of its success, accounting for a significant portion of the company’s total revenue. The segment achieved 648 million USD in net sales for the first quarter, reflecting a year-on-year growth of 13.1% at constant currency. Neuromodulators like Dysport and Relfydess led the surge in sales, thanks to strong performances in the European and Asia Pacific regions, as well as favorable conditions in the U.S. market.
The company’s ongoing commitment to innovation was also highlighted with recent regulatory progress for Relfydess in various markets, strengthening its competitive edge. Galderma is dedicated to enhancing the consumer experience by addressing emerging needs, including research on the implications of menopause on skin health, thereby reinforcing its status as a leader in the aesthetics space.
Dermatological Skincare Shows Robust Momentum
Galderma’s Dermatological Skincare segment, which includes well-known brands like Cetaphil and Alastin, generated 441 million USD in sales, indicating a year-on-year increase of 17%. This growth can be attributed to strategic marketing initiatives and the launch of new products designed to meet diverse consumer needs.
Both flagship brands have maintained strong sales momentum, benefitting from a conducive market environment and innovative product offerings. Cetaphil’s expansion into fast-growing international markets, particularly in Asia, and Alastin’s partnerships with top aesthetic clinics in the U.S. have significantly bolstered the segment’s performance. The introduction of advanced formulations such as AM/PM Antioxidant Serums and Alastin Regenerating Skin Nectar also underlines the company’s continued focus on product innovation.
Therapeutic Dermatology: Leading the Way with New Launches
Galderma’s Therapeutic Dermatology segment exhibited extraordinary growth, with net sales climbing to 385 million USD, up 71.3% year-on-year. This significant increase was largely driven by the successful launch of Nemluvio, a treatment for moderate-to-severe atopic dermatitis. The product demonstrated an impressive uptake in the U.S. market, capturing nearly 39% of the market share in prurigo nodularis within just a few months of its availability.
The launch trajectory for Nemluvio remains strong, with patient starts primarily comprising individuals new to biologics, thus expanding the addressable market. Galderma’s efforts in engaging healthcare professionals through real-world evidence further emphasize its commitment to ensuring the effective use of its products and enhancing patient outcomes across various therapeutic areas.
Financial Strength and Strategic Initiatives Enhance Shareholder Returns
Galderma has made considerable strides in solidifying its financial foundation, evidenced by its successful Eurobond issuance of 500 million EUR to facilitate the full repayment of its Term Loan. Coupled with share repurchases and a recent dividend declaration of 0.35 CHF per share, the company showcases its dedication to delivering shareholder value while maintaining a robust liquidity position.
The shift to a free-float-dominated shareholder base, marked by the complete divestment of EQT-led consortium investors, positions Galderma for long-term strategic flexibility. This represents a record-breaking capital gain for a single private equity fund, further enhancing the company’s profile in the global market.
Looking Ahead: Confirming Robust Full-Year Guidance
As Galderma navigates the evolving landscape of the dermatology market, it remains optimistic about its financial outlook for 2026. The company expects net sales growth between 17% and 20% at constant currency, along with a core EBITDA margin of approximately 26%. Galderma’s confidence is underpinned by its strong first-quarter performance, strategic product launches, and expansion initiatives that are set to meet the demands of a volatile market.
The continued emphasis on innovation, marked by successful clinical results and product launches, positions Galderma as a leader in the dermatology sector. The company aims to capitalize on significant growth opportunities in 2026, focusing on expanding its reach in key markets, gaining market share, and enhancing its financial resilience.
What This Means Going Forward
With a solid start to 2026, Galderma is poised for sustained growth in the dermatology market. As the company continues to innovate and expand its product offerings, it remains committed to addressing the evolving needs of consumers and healthcare professionals alike. The anticipated advancements in product development and market reach will likely further establish Galderma’s leadership position in the dynamic dermatology landscape.
For more detailed insights into Galderma’s financial performance, you can visit the company’s investor relations page[here](https://investors.galderma.com/events-presentations). Additionally, to explore recent trends in the aesthetics market, refer to reports by[BBC](https://www.bbc.com) and[Reuters](https://www.reuters.com) that discuss the growth of the global beauty and dermatology sectors.
According to a report by[Business Wire](https://www.businesswire.com/news/home/20260422930888/en/), Galderma’s strategic focus on dermatology continues to reshape the industry, driven by innovation, strong financial performance, and market responsiveness.
